SEC Form 4 · accession 0001209191-18-053764
Tvardi Therapeutics, Inc. · TVRD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Frederique Menzaghi Ph.D.
Officer — Sr VP-Research & Development
Period of report
Oct 1, 2018
Accepted (ET)
Oct 3, 2018 · 4:09 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001346830
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Oct 1, 2018 | S | 3,000 | $23.99 | D | 95,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2017.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.90 to $24.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.